Anti‐VEGF therapy combined with immune checkpoint inhibitors (ICIs) has shown synergistic effects by enhancing immune cell infiltration and reducing tumor‐mediated immunosuppression, thereby improving response rates and survival. This evidence concerns the gene VEGFA and neoplasm.